Bumex (bumetanide) is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required, and dose and dosage schedule have to be adjusted to the individual patient's needs (see DOSAGE AND ADMINISTRATION).
Bumex® (bumetanide) is a loop diuretic, available as scored tablets, 0.5 mg (light green), 1 mg (yellow) and 2 mg (peach) for oral administration; each tablet also contains lactose, magnesium stearate, microcrystalline cellulose, cornstarch and talc, with the following dye systems: 0.5 mg—D&C Yellow No. 10 and FD&C Blue No. 1; 1 mg—D&C Yellow No. 10; 2 mg—red iron oxide.
Bumex is indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome.
Almost equal diuretic response occurs after oral and parenteral administration of bumetanide. Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route.
Successful treatment with Bumex following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity.
Published Studies Related to Bumex (Bumetanide)
The use of bumetanide for oliguric acute renal failure in preterm infants. [2011.03]
OBJECTIVE: To determine the effects of bumetanide in preterm infants with oliguric acute renal failure (OARF)... CONCLUSIONS: Bumetanide therapy significantly increased urine output within 24-48 hrs, but its use was associated with a transient increase in serum creatinine level. Bumetanide can be used in preterm infants to reverse oliguria when therapy with furosemide fails. Prospective, randomized, controlled trials with long-term follow-up in preterm infants are necessary to establish the usefulness of bumetanide for OARF.
The use of bumetanide for oliguric acute renal failure in preterm infants. [2010.07.09]
OBJECTIVE:: To determine the effects of bumetanide in preterm infants with oliguric acute renal failure (OARF)... CONCLUSIONS:: Bumetanide therapy significantly increased urine output within 24-48 hrs, but its use was associated with a transient increase in serum creatinine level. Bumetanide can be used in preterm infants to reverse oliguria when therapy with furosemide fails. Prospective, randomized, controlled trials with long-term follow-up in preterm infants are necessary to establish the usefulness of bumetanide for OARF.
Loop Diuretics Increase Bone Turnover and Decrease BMD in Osteopenic Postmenopausal Women: Results From a Randomized Controlled Study With Bumetanide. [2006.01]
To study effects of loop diuretics on bone, 87 women were randomized to 1 year of treatment with bumetanide or placebo. Compared with placebo, bumetanide decreased BMD by 2% at the total hip and by 1.4% at the whole body. Levels of biochemical bone markers were lower in the placebo than in the bumetanide group. Thus, treatment with loop diuretics affects bone metabolism. INTRODUCTION: Loop diuretics may affect bone because they increase the renal calcium excretion and alters the diurnal rhythm of plasma PTH levels. We studied the effects of 1 year of treatment with the loop diuretic bumetanide on bone metabolism... CONCLUSIONS: Treatment with loop diuretics affects bone turnover and decreases BMD. Further studies may reveal whether loop diuretics should be considered as a risk factor for fracture.
Age- and region-specific effects of anticonvulsants and bumetanide on 4-aminopyridine-induced seizure-like events in immature rat hippocampal-entorhinal cortex slices. [2011.01]
PURPOSE: Seizure-like events (SLEs) induced by 4-aminopyridine in rat organotypic slices cultures, which are prepared early after birth, are resistant to standard antiepileptic drugs. In this study we tested the hypothesis that pharmacoresistance may be an intrinsic property of the immature brain... CONCLUSION: We conclude that pharmacoresistance may be inherent to very immature tissue and suggest that expression of the NKCC1 cotransporter might contribute to pharmacoresistance. Wiley Periodicals, Inc. (c) 2010 International League Against Epilepsy.
The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects. [2010.12]
The inhibitory transmitter GABA has been suggested to play an important role in infantile autistic syndrome (IAS), and extensive investigations suggest that excitatory actions of GABA in neurological disorders are because of a persistent increase of [Cl(-) ](I) . AIMS: To test the effects of the chloride co-transporter NKCC1 diuretic compound Bumetanide that reduces [Cl(-) ](I) on IAS... CONCLUSION: Bumetanide decreases autistic behaviour with no side effects suggesting that diuretic agents may exert beneficial effects on IAS and that alterations of the actions of GABA may be efficient in IAS treatment calling for large scale randomized trials. (c) 2010 The Author(s)/Acta Paediatrica (c) 2010 Foundation Acta Paediatrica.
Clinical Trials Related to Bumex (Bumetanide)
Pilot Study of Bumetanide for Newborn Seizures [Recruiting]
The main goal of the study is to obtain pharmacokinetic and safety data of bumetanide in
newborns with refractory seizures. The overall hypothesis is that bumetanide, added to
conventional antiepileptic (antiseizure) medications, will be a safe and well tolerated
medication, compared with conventional antiepileptic drugs alone.
Bumetanide Versus Furosemide in Heart Failure [Not yet recruiting]
Patients with NYHA FC II-III heart failure will be randomized in a cross-over fashion to 8
weeks of bumetanide versus furosemide therapy (equipotent dose), to test whether bumetanide
therapy has a superior effect on insulin resistance compared to furosemide. Patients will be
subject to a frequently sampled intravenous glucose tolerance test (FSIGT) with minimal
model (MINMOD) analysis to assess insulin resistance and to a 6-minute walk test (6MWT) to
assess functional capacity; patient recruitment and retention success, as well as medication
adherence, will also be assessed.
NEMO1:NEonatal Seizure Using Medication Off-patent [Recruiting]
NEMO is a multicentre pan European clinical trial with the aim to develop new treatment
strategies for the treatment of neonatal seizures using the loop diuretic bumetanide. There
is evidence that bumetanide improves GABAergic function of the current standard drug,
phenobarbitone. Bumetanide has been used as a diuretic in term and preterm babies for around
thirty years. This trial should confirm that Bumetanide in addition to standard treatment
will result in better seizures control.
Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects [Recruiting]
To assess the potential pharmacokinetic (PK) interactions of bumetanide and dapagliflozin
following multiple doses of 1 mg bumetanide and 10 mg dapagliflozin in healthy subjects
Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics [Recruiting]
The purpose of this research study is to compare the effects (good and bad) of
ultrafiltration treatment with standard intravenous (in your vein) diuretic therapy on your
heart function and blood flow.
Reports of Suspected Bumex (Bumetanide) Side Effects
Drug Administration Error (2),
Wrong Drug Administered (1),
Abnormal Dreams (1), more >>
Page last updated: 2011-12-09